These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 23313932)

  • 1. Cost-effectiveness of adjuvant FOLFOX and 5FU/LV chemotherapy for patients with stage II colon cancer.
    Ayvaci MU; Shi J; Alagoz O; Lubner SJ
    Med Decis Making; 2013 May; 33(4):521-32. PubMed ID: 23313932
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CDX2 Biomarker Testing and Adjuvant Therapy for Stage II Colon Cancer: An Exploratory Cost-Effectiveness Analysis.
    Alarid-Escudero F; Schrag D; Kuntz KM
    Value Health; 2022 Mar; 25(3):409-418. PubMed ID: 35227453
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The clinical and cost-effectiveness of oxaliplatin and capecitabine for the adjuvant treatment of colon cancer: systematic review and economic evaluation.
    Pandor A; Eggington S; Paisley S; Tappenden P; Sutcliffe P
    Health Technol Assess; 2006 Nov; 10(41):iii-iv, xi-xiv, 1-185. PubMed ID: 17049138
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness analysis of capecitabine compared with bolus 5-fluorouracil/l-leucovorin for the adjuvant treatment of colon cancer in Japan.
    Shiroiwa T; Fukuda T; Shimozuma K; Ohashi Y; Tsutani K
    Pharmacoeconomics; 2009; 27(7):597-608. PubMed ID: 19663530
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of adjuvant FOLFOX therapy for stage III colon cancer in Japan based on the MOSAIC trial.
    Shiroiwa T; Takeuchi T; Fukuda T; Shimozuma K; Ohashi Y
    Value Health; 2012; 15(2):255-60. PubMed ID: 22433756
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized phase III trial of adjuvant chemotherapy with irinotecan, leucovorin and fluorouracil versus leucovorin and fluorouracil for stage II and III colon cancer: a Hellenic Cooperative Oncology Group study.
    Papadimitriou CA; Papakostas P; Karina M; Malettou L; Dimopoulos MA; Pentheroudakis G; Samantas E; Bamias A; Miliaras D; Basdanis G; Xiros N; Klouvas G; Bafaloukos D; Kafiri G; Papaspirou I; Pectasides D; Karanikiotis C; Economopoulos T; Efstratiou I; Korantzis I; Pisanidis N; Makatsoris T; Matsiakou F; Aravantinos G; Kalofonos HP; Fountzilas G
    BMC Med; 2011 Jan; 9():10. PubMed ID: 21281463
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness analysis of colon cancer treatments from MOSIAC and No. 16968 trials.
    Wen F; Yao K; Du ZD; He XF; Zhang PF; Tang RL; Li Q
    World J Gastroenterol; 2014 Dec; 20(47):17976-84. PubMed ID: 25548497
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness analysis of oxaliplatin compared with 5-fluorouracil/leucovorin in adjuvant treatment of stage III colon cancer in the US.
    Aballéa S; Chancellor JV; Raikou M; Drummond MF; Weinstein MC; Jourdan S; Bridgewater J
    Cancer; 2007 Mar; 109(6):1082-9. PubMed ID: 17265519
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of Duration and Effects of 3 vs 6 Months of Adjuvant Chemotherapy in High-Risk Stage II Colorectal Cancer: A Subgroup Analysis of the TOSCA Randomized Clinical Trial.
    Petrelli F; Labianca R; Zaniboni A; Lonardi S; Galli F; Rulli E; Rosati G; Corallo S; Ronzoni M; Cardellino GG; Mattioli R; Mambrini A; Ciuffreda L; Banzi M; Pusceddu V; Maiello E; Zampino M; Zagonel V; Marchetti P; Corsi D; Rimassa L; Cinieri S; Sobrero A
    JAMA Oncol; 2020 Apr; 6(4):547-551. PubMed ID: 32053133
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost effectiveness analysis of pharmacokinetically-guided 5-fluorouracil in FOLFOX chemotherapy for metastatic colorectal cancer.
    Goldstein DA; Chen Q; Ayer T; Howard DH; Lipscomb J; Harvey RD; El-Rayes BF; Flowers CR
    Clin Colorectal Cancer; 2014 Dec; 13(4):219-25. PubMed ID: 25306485
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sex and Adverse Events of Adjuvant Chemotherapy in Colon Cancer: An Analysis of 34 640 Patients in the ACCENT Database.
    Wagner AD; Grothey A; Andre T; Dixon JG; Wolmark N; Haller DG; Allegra CJ; de Gramont A; VanCutsem E; Alberts SR; George TJ; O'Connell MJ; Twelves C; Taieb J; Saltz LB; Blanke CD; Francini E; Kerr R; Yothers G; Seitz JF; Marsoni S; Goldberg RM; Shi Q
    J Natl Cancer Inst; 2021 Apr; 113(4):400-407. PubMed ID: 32835356
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-utility analysis of the newly recommended adjuvant chemotherapy for resectable gastric cancer patients in the 2011 Chinese National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology: Gastric Cancer.
    Chongqing T; Liubao P; Xiaohui Z; Jianhe L; Xiaomin W; Gannong C; Siying W; Lihui O; Ziying Z
    Pharmacoeconomics; 2014 Mar; 32(3):235-43. PubMed ID: 23709451
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-utility analysis of adjuvant chemotherapy in patients with stage III colon cancer in Thailand.
    Lerdkiattikorn P; Chaikledkaew U; Lausoontornsiri W; Chindavijak S; Khuhaprema T; Tantai N; Teerawattananon Y
    Expert Rev Pharmacoecon Outcomes Res; 2015; 15(4):687-700. PubMed ID: 25327502
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of adverse events during 5-fluorouracil versus 5-fluorouracil/oxaliplatin adjuvant chemotherapy for stage III colon cancer: a population-based analysis.
    Sanoff HK; Carpenter WR; Freburger J; Li L; Chen K; Zullig LL; Goldberg RM; Schymura MJ; Schrag D
    Cancer; 2012 Sep; 118(17):4309-20. PubMed ID: 22294436
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness analysis of cetuximab combined with chemotherapy as a first-line treatment for patients with RAS wild-type metastatic colorectal cancer based on the TAILOR trial.
    Wang H; Huang L; Gao P; Zhu Z; Ye W; Ding H; Fang L
    BMJ Open; 2020 Feb; 10(2):e030738. PubMed ID: 32051297
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adjuvant FOLFOX chemotherapy and splenomegaly in patients with stages II-III colorectal cancer.
    Angitapalli R; Litwin AM; Kumar PR; Nasser E; Lombardo J; Mashtare T; Wilding GE; Fakih MG
    Oncology; 2009; 76(5):363-8. PubMed ID: 19321964
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Clinical and Cost Effectiveness of Aflibercept in Combination with Irinotecan and Fluorouracil-Based Therapy (FOLFIRI) for the Treatment of Metastatic Colorectal Cancer Which has Progressed Following Prior Oxaliplatin-Based Chemotherapy: a Critique of the Evidence.
    Wade R; Duarte A; Simmonds M; Rodriguez-Lopez R; Duffy S; Woolacott N; Spackman E
    Pharmacoeconomics; 2015 May; 33(5):457-66. PubMed ID: 25616671
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative and cost-effectiveness of oxaliplatin-based or irinotecan-based regimens compared with 5-fluorouracil/leucovorin alone among US elderly stage IV colon cancer patients.
    Mullins CD; Hsiao FY; Onukwugha E; Pandya NB; Hanna N
    Cancer; 2012 Jun; 118(12):3173-81. PubMed ID: 22020739
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Markov model assessing the effectiveness and cost-effectiveness of FOLFOX compared with FOLFIRI for the initial treatment of metastatic colorectal cancer.
    Tumeh JW; Shenoy PJ; Moore SG; Kauh J; Flowers C
    Am J Clin Oncol; 2009 Feb; 32(1):49-55. PubMed ID: 19194125
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative effectiveness of different chemotherapeutic regimens on survival of people aged 66 and older with stage III colon cancer: a "real world" analysis using Surveillance, Epidemiology, and End Results-Medicare data.
    Hsiao FY; Mullins CD; Onukwugha E; Pandya N; Hanna N
    J Am Geriatr Soc; 2011 Sep; 59(9):1717-23. PubMed ID: 21831168
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.